Summary
This prediction ended on 19.03.18 with a price of €14.55. The BUY prediction by melinda for GSK plc closed nearly unchanged. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| GSK plc | 2.232% | 2.232% | 29.224% | 26.928% |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% | 68.786% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% | 100.066% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% | 43.024% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% | 63.222% |
According to melinda what are the pros and cons of GSK plc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread GlaxoSmithKline plc diskutieren
Pharmazeutische SecteurProduits Agenda 25/04 Ergebnisse Veröffentlichung
GSK stellt fest , dass ViiV Healthcare verkündet positive Daten Dolutegravir
5. März (Reuters) - Glaxosmithkline Plc :: GLAXOSMITHKLINE PLC - ViiV Healthcare KÜNDIGT NEUE DATEN ZUR BEHANDLUNG VON MENSCHEN POSITIVE Dolutegravir mit HIV-Infizierte mit TUBERCULOSIS.GLAXOSMITHKLINE CO PLC - Dolutegravir WANN 50mg zweimal täglich zu MIT NUCLEOSID DOUBLE REVERSE.